MedTrace Logo

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

NCT00166322 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2008-05-07

No results posted yet for this study

Summary

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Conditions

Interventions

PROCEDURE

IBZM-SPECT (bolus and constant infusion paradigm)

single IBZM-SPECT assessment at study inclusion

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Oliver Pogarell, MD · Dept. of Psychiatry, University of Munich

  • Klaus Tatsch, MD · Dept. of Nuclear Medicine, University of Munich

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00166322 on ClinicalTrials.gov